ORAL ANTI-CD3 IMMUNOTHERAPY FOR HCV-NON-RESPONDERS IS SAFE, PROMOTES REGULATORY T CELLS, AND DECREASES VIRAL LOAD AND LIVER ENZYME LEVELS: RESULTS OF A PHASE-2a PLACEBO-CONTROLLED TRIAL
JOURNAL OF HEPATOLOGY（2013）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要